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Summary E1000, the most drug-resistant subline from the E-series (CCRF-CEM/E16 to E1000), has been previously shown to express high
mRNA levels from two ABC transporter genes associated with multidrug resistance, ARA and MRP. The expression and amplification of both
genes has now been characterized for each member of the E-series of drug-resistant sublines and is reported here. Both ARA [detected by
reverse transcriptase polymerase chain reaction (RT-PCR)] and MRP(detected by Northern blot analysis) were expressed at low levels in the
sensitive parental CEM cell line. An equivalent level of MRP mRNA expression was detected throughout the CEM, E16, E25 and E50
sublines, and there was increasing expression in the El00, E200 and El000 sublines. ARA expression was not detected in the El6, E25, E50
and E100 sublines but was detected by both RT-PCR and Northern blot analysis in the E200 and E1000 sublines. Southern blot analysis
indicated the increased levels of MRP and ARA expression resulted from gene amplification and that MRP was first amplified in the E100
subline and ARA in the E200 subline, suggesting that the two genes were not initially co-amplified. Cytogenetic analysis of E1000 cells
demonstrated a large addition to chromosome 16p, around the region where the ARA and MRP genes are located. Increased expression of
ARA is associated with increased colchicine resistance in the E-series of sublines and combined with MRP may account for their resistance
phenotype.
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The occurrence ofthe multidrug resistance (MDR) phenotype is still
a major obstacle to the successful treatment of cancer. It now
appears that overexpression of a number of ATP-binding cassette
(ABC) transporter proteins is, at least partially, responsible for the
MDR phenotype. Two ABC transporters that have been shown to
confer drug resistance are P-glycoprotein (Gottesman and Pastan,
1993) and the multidrug resistance-associated protein (MRP) (Grant
et al, 1994). Other ABC transporters that have recently been impli-
cated in drug resistance include the human canalicular multispecific
organic anion transporter (c-MOAT) (Taniguchi et al, 1996), ABC-
C (Klugbauer and Hoffman, 1996), the transporter associated with
antigen processing (TAP) (Izquierdo et al, 1996) and the anthra-
cycline resistance-associated (ARA) protein (Longhurst et al, 1996).
ABC transporters have been implicated in MDR as a result of
studies carried out on MDR cell sublines produced by exposure to
stepwise increasing drug concentrations. The E-series ofMDR cell
sublines was developed by treatment of the T-cell leukaemia cell
line CCRF-CEM (Foley et al, 1965) with increasing levels of the
anthracycline epirubicin (Davey et al, 1995). This series contains
sublines displaying increasing levels of MDR, beginning with the
E16 (resistant to 16 ng ml-' epirubicin) through to the EI000
subline (resistant to 1000 ng ml-' epirubicin). Thus, the E-series
provides a model in which to determine the relationship between
the level ofMDR and the expression ofMDR mechanism(s).
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Previously, we have shown that MRP expression parallels the
observed increase in drug resistance in the members of the E-
series (Davey et al, 1995) and that both ARA and MRP are ampli-
fied in the EIOOO subline (Longhurst et al, 1996). ARA has
recently been mapped to human chromosome 16p13.1 (Dr B Kuss,
personal communication) in the vicinity ofMRP at 16p13.13 (Cole
et al, 1992) and confirmed by the recent release of sequence
data from human chromosome 16pll3 (GenBank accession code
U91318). The amplification states ofthe ARA and MRP genes and
the level of ARA expression have not been reported in the
remaining members ofthe E-series. This study reports the relation-
ships between ARA and MRP gene amplification and expression
and drug cross-resistance in the E-series of sublines.
MATERIALS AND METHODS
Cell lines
The human leukaemia cell line CCRF-CEM (CEM) (Foley et al,
1965), and its epirubicin selected drug-resistant sublines, E16,
E25, E50, E100, E200 and E1000 (E-series) (Davey et al, 1995),
were maintained as suspension cultures at 37°C in a humidified
atmosphere with 5% carbon dioxide, either in RPMI-1640
medium (Trace Biosciences, Sydney, Australia) containing 10%
fetal calf serum (Trace Biosciences) and supplemented with
10 mm sodium hydrogen carbonate and 20 mM Hepes or in alpha-
MEM (ICN, Sydney, Australia), as previously described (Davey et
al, 1995). Exponentially growing cells were used for all experi-
ments and all cell cultures were free ofmycoplasma.
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Figure 2 Amplification of ARA and MRPin the E-series of sublines.
Genomic DNA extracted from each of the sublines and from the CEM cells
was digested with the restriction enzyme Xbal and analysed by Southern blot
hybridization with the [32P]dCTP-labelled (A) ARA and (B) MRP probes.
Southern blot analysis was carried out on six separate occasions and
representative blots are shown. The three bands of hybridization visible on
each blot are the characteristic Xbal-digested fragments of genomic DNA
that hybridize with the ARA and MRPprobes respectively. Positions of DNA
markers are indicated
Figure 1 Cytogenetic analysis of the El000 subline. (A) GTL-banded partial
karyotypes of two metaphases from El000 cells. Normal chromosome 16
and those with the large addition to the short arm are indicated. Also
indicated is the distal limit of the chromosome 16 paint (<) for the 16p
addition (based on FISH data), and the map position of ARA/MRP in the
normal 16 (**). Two normal copies of 16 and one copy of the large derivative
16 are present. An unbalanced translocation of 16q was also seen in most
cells (G-bands not shown, but seen Figure 1B for FISH). (B) FISH analysis of
a partial metaphase spread from El000, using 16-specific whole-
chromosome paint, and showing the four elements mentioned above. These
four are labelled with two large arrowheads (two normal 16s); a small
arrowhead (unbalanced 16q translocation); and a large bracket, indicating the
full length of the large derivative 16. Note that one end of this large
chromosome does not label with 16 paint. The point at which painted and
unpainted segments abut corresponds to the region labelled < in Figure 1A
Drugs and chemicals
Vinblastine and vincristine were purchased from David Bull
(Melbourne, Australia), epirubicin and doxorubicin from
Pharmacia (Melbourne, Australia), daunorubicin from May and
Baker (Melbourne, Australia), etoposide from Bristol (Sydney,
Australia) and colchicine and actinomycin D from Sigma (St Louis,
MO, USA). All other reagents were ofanalytical reagent grade.
Cytogenetic and fluorescence in situ hybridization
(FISH) studies
Cell lines were cultured and harvested using established tech-
niques for GTL banding. FISH analysis was carried out using
FITC/biotin/avidin chromosome 16-specific paint as per the
manufacturer's instructions (CamBio, Cambridge, UK), with one
round of amplification. Chromosomes were counterstained with
DAPI, and digital images captured using a CCD camera.
DNA probes
cDNA inserts were excised from plasmid constructs by restriction
enzyme digestion and the gel-purified inserts were labelled with
[32P]dCTP using a random primed DNA labelling kit (Boehringer
Mannheim, Sydney, Australia). The plasmid pmrplO.1 was grate-
fully obtained from SPC Cole and RG Deeley (Cole et al, 1992)
and the 1000-bp EcoRl nucleotide fragment was used to probe for
MRP. The ARA probe consisted ofa 1000-bp SacI-NotI restriction
fragment isolated from the clone encoding ARA (Longhurst et al,
1996). A 600-bp fragment of mouse ,-actin, excised by digestion
with PstI, was used to standardize RNA loading.
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Figure 3 Expression of ARA and MRP in the E-series of sublines. Total
RNA extracted from the indicated cell lines was analysed by Northern blot
hybridization with the [32P]dCTP labelled (A) ARA and (B) MRP probes.
f-Actin expression was used as an indicator of the amount of sample
loaded and the sizes of mRNA species are indicated
Southern blot analysis
Genomic DNA was extracted from each subline as described
previously (Sambrook et al, 1989). DNA was digested with the
restriction enzyme Xba I and 10 ,ug of each digest separated by
electrophoresis in a 0.5% agarose gel. Separated DNA was trans-
ferred to Zetaprobe GT membrane (BioRad, Sydney, Australia)
and hybridization carried out as described previously (Longhurst
et al, 1996) at 65°C.
Northern blot analysis
Total RNA was extracted from each subline using guanidine thio-
cyanate as described previously (Chomcyznski and Sacchi, 1987).
Extracted RNA was separated by electrophoresis in % agarose
gels and transferred to Zetaprobe GT membrane as described
previously (Sambrook et al, 1989). Aliquots of either 20 ,ug or
30 jig of total RNA were loaded in each well for hybridization
with the MRP and ARA probes respectively. Hybridizations were
carried out at 42°C in 50% formamide as described by Sambrook
et al (1989).
Reverse transcription polymerase chain reaction
(RT-PCR)
Reverse transcription reactions were carried out on 2.5 jg total
RNA, extracted as described above. Reactions were performed in a
20-gl reaction volume using 1 gM random hexamers (Gibco-BRL,
Melbourne, Australia) per reaction with Superscript II RNAse H-
reverse transcriptase according to the manufacturer's instructions
(Gibco-BRL). Reverse transcription reactions were diluted with
180 jl of Milli-Q water and 15 jl aliquots were then used in PCR
reactions. Reactions were performed with primer pairs for ARA
(ARA2F: 5'-ACACCCATTGGTCACCTGCTA-3' and ARA2R:
5'-GGTCACCTGGAGGGCAGCAGAGAC-3' designed by Dr B
Kuss, personal communication) and, in separate reactions, with
control primer pairs for P-actin (Stratagene, La Jolla, CA, USA).
PCR constituents [RNA template, 1.5 mm magnesium chloride,
1 ,UM each of ARA2F and ARA2R, 0.2 mM dNTPs and reaction
-ARA (324 bp)
-Actin (661 bp)
Figure 4 Expression of ARA in the E-series of sublines determined by
RT-PCR. Separate PCR reactions were carried out on the indicated reverse
transcribed RNA samples using primers for ARA and j-actin. The PCR
products were electrophoretically separated in 5% polyacrylamide gels and
their sizes are indicated
buffer according to the manufacturer's protocol (Perkin-Elmer,
Sydney, Australia)] were incubated under mineral oil in 0.5-ml
thin-walled tubes (Perkin-Elmer) for S min at 95°C, 1.25 units of
AmpliTaq enzyme (Perkin-Elmer) was then added to each reaction
and the following protocol was carried out in an Omne thermo-
cycler (Stratagene): 95°C (2.5 min), 65°C (3 min), 72'C (5 min) for
one cycle; 95°C (45 s), 65°C (1 min), 72°C (1 min) for 35 cycles;
and 72°C 10 min extension time. Negative controls, consisting of
PCR reagents with Milli-Q water substituted for template DNA,
were included with each set of PCR reactions. Products were
analysed by electrophoresis through 5% polyacrylamide gels.
Cytotoxicity assays
The cytotoxicity of each drug was determined using an MTT cell
viability assay (Marks et al, 1992). Each determination was in trip-
licate and all experiments were repeated at least once. The IC50
value (drug concentration causing 50% decreased in MTT produc-
tion) was determined and the relative resistance was calculated by
dividing the IC () for each subline by that of the CEM line.
RESULTS
Amplification of ARA and MRP
Figure IA shows a partial GTL-banded karyotype of two cells
from the E1000 subline. Clearly evident is a large addition to 16p,
shown by whole-chromosome paint to comprise chromosome 16
material, except for the extreme distal region (Figure 1B).
Southern blots of DNA extracted from each member of the E-
series of drug-resistant sublines and the parental CEM cell line
were assayed with cDNA probes forARA and MRP. An equivalent
level of ARA hybridization was detected in the CEM, E16, E25,
E50 and E100 cell lines and increased hybridization was detected
for the E200 and E1000 cell lines (Figure 2A), suggesting that
ARA was amplified in the last two sublines. The level of MRP
hybridization to DNA from CEM, E16, E25 and E50 sublines did
not change, however there was increased hybridization detected in
the E100, E200 and EIOOO cell lines (Figure 2B), suggesting that
MRP was amplified in these sublines.
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Expression of ARA and MRP
Northern blot analysis oftotal RNA extracted from the E-series of
drug-resistant sublines demonstrated that ARIA mRNA could only
be detected in the E200 and E1000 sublines (Figure 3A). Longer
exposure time of the autoradiograph did not result in detection of
ARA mRNA in the less drug-resistant sublines (results not shown).
A low level of MRP mRNA was detected in the CEM cells and
similar levels were detected in the E16, E25 and E50 sublines
(Figure 3B). Increasing levels ofMRP mRNA were detected in the
EI00, E200 and EI000 sublines. Probing with 1-actin demon-
strated that all RNA loadings were equal (Fig 3A and B).
RT-PCR was carried out on total RNA extracted from each
member of the E-series. PCR with the ARA primer pair resulted in
a product of the expected size (324 bp) detected faintly in the
CEM sample and clearly in both the E200 and EIOOO samples
(Figure 4). A second band, of less than 300 bp, observed in the
CEM lane disappeared with decreasing concentration of Mg2+ in
the PCR reaction (results not shown). To ensure that the negative
results observed with the other sublines were not due to template
problems, control PCR reactions with the 3-actin primer pair were
carried out on all reverse-transcribed samples. Figure 4 demon-
strates that a band ofthe expected size (661 bp) was observed in all
samples, indicating that each reverse-transcribed sample could be
amplified in the PCR. In addition, template-negative PCR controls
gave no PCR products. Therefore, ARA expression was not
detected in the E16, E25, E50 and EIOO sublines by RT-PCR.
Drug cross-resistance profiles of the E-series of
sublines
Each subline from the series was assayed for resistance to treat-
ment with actinomycin D, vinblastine, colchicine, vincristine,
daunorubicin, doxorubicin, epirubicin and etoposide, and the fold
resistance relative to the CEM parent cell line was calculated
(Figure 5). Each subline was resistant to all the anthracyclines and
etoposide with the E16, E25 and E50 sublines exhibiting similar
levels ofresistance (three- to tenfold). The E100, E200 and E1000
sublines showed increasing resistance to these drugs and to
vincristine. Resistance to colchicine was first detected in the E200
subline and this was increased in the EIOOO subline.
DISCUSSION
The results presented here have demonstrated that the amplifica-
tion ofARA in the E200 and EIOOO sublines plus amplification of
MRP in the E100, E200 and El000 sublines (Figure 2) most prob-
ably account for the increased expression of these two genes as
shown by Northern blot analysis of ARA and MRP expression
(Figure 3) and in earlier analyses ofMRP expression (Davey et al,
1995). In the E1OO0 subline, this amplification is associated with a
large addition to chromosome 16p (Figure lA), which contains
much chromosome 16 material as demonstrated by the chromo-
some 16 paint (Figure IB). This segment comprises a novel
banding pattern, implicating multiple and complex rearrange-
ments. Changes of this nature have been associated with other
examples of gene amplification, mediated through the breakage-
fusion-bridge (or BFB) cycle (Smith et al, 1992; Toledo et al,
1992). For a number of cell generations, this cycle engenders a
massive and sustained increase in the duplication and deletion rate
within the involved chromosome(s). As such, the BFB cycle
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Figure 5 Drug cross-resistance of the E-series of sublines. The fold
resistance of each subline relative to the CEM cells was determined for the
indicated drugs using the MUT cell viability assay. -0-, Etoposide; - -U- -,
epirubicin; - -A- -, doxorubicin; - -*- -, daunorubicin; - -V- - vincristine; -A-,
colchicine; - -7- - vinblastine; --x--, actinomycin-D
imposes a transient mutator phenotype on any cell acquiring a
dicentric chromosome. Such dicentric chromosomes are very
likely to arise during in vivo use ofclastogenic, therapeutic drugs.
The BFB cycle can thus be regarded as of oncogenic significance,
similar in potential to mutations that increase the mutation rate at
the molecular rather than the cytogenetic level (Eshleman and
Markowitz, 1996; Loeb, 1997). Amplifications arising through the
BFB cycle accrue gradually, originating as gene duplications only
(Smith et al, 1992). However, the relatively high levels of gene
amplification seen in cultured drug-resistant sublines can also be
achieved through the BFB cycle, given that the BFB can proceed
in vitro over a much greater number ofcell generations than occur
in vivo, during the clinical course ofmalignancy.
Both ARA and MRP have been mapped to the short arm of
chromosome 16. MRP has been localized to 16pll3.13 (Cole et al,
1992) and ARA has been localized to l6pl3.1 (Dr B Kuss,
personal communication). The close proximity of the two genes
suggests that they could be co-amplified. However, the observa-
tion that MRP is first amplified in the E1OO subline and ARA and
MRP are amplified in the E200 subline indicates that the co-ampli-
fication was secondary to and, to some extent, independent of the
original MRP amplification in the E100 subline. In support ofthis,
cytogenetic analyses of the EIOO subline show another 16p addi-
tion, differing in size and banding pattern from that observed in the
EIO1O subline (Peters et al, manuscript in preparation). The
presence of multiple amplifications, arising in related but distinct
cytogenetic subclones, is also compatible with amplification via
the BFB cycle (Ma et al, 1993).
Others have reported that MRP amplification corresponds to
increased MRP expression in a variety of MDR sublines (Cole et
al, 1992; Krishnamachary et al, 1994; Slapak et al, 1994; Binaschi
et al, 1995; Slovak et al, 1995). The MDR human small-cell lung
cancer sublines, GLC4/ADR and H69/AR, contain amplified MRP
in double-minute chromosomes and additions to various chromo-
somes other than 16 (Eijdems et al, 1995; Slovak et al, 1993). The
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MDR HT1080/DR4 fibrosarcoma subline contains amplified MRP
in additions to chromosome 7 (Slovak et al, 1995). The MDR
HL60/AR subline has additions to chromosome 7 but also has
augmentation of the 16p13.1 region containing the MRP gene
(Cole et al, 1992). In comparison, the EIOOO subline appears to
contain no double-minute chromosomes but a large augmentation
of 16p. These examples of sublines containing amplification of
MRP were all selected with a DNA disrupting drug, which may
initiate the amplification process by causing chromosome
breakage and reciprocal gains and losses of genetic material (Ma
et al, 1993). Cells carrying amplifications resulting from breaks
in the vicinity of drug resistance loci may then be selected for by
the presence of the drug. This selective advantage may not just
involve MRP but it may also include otherputative drug-resistance
genes near this region on 16p such as ARA, the major vault
protein or lung resistance protein gene, LRP, located at l6pl1.2
(Slovak et al, 1995) andABC-C located at 16plI3.3 (Klugbauer and
Hoffman, 1996).
The drug cross-resistance of each member of the E-series,
presented here (Figure 5) and reported previously (Davey et al,
1995), suggests that MDR has developed in two phases. The first
phase, corresponding to lower levels of MDR, is observed in the
E16, E25 and E50 sublines. This is associated with no significant
change in MRP expression relative to that in the CEM cells, which
suggests that either MRP is not involved in this low level MDR or,
alternatively, the 'activity' of MRP may be altered in these
sublines. The first phase appears also to be associated with
decreased ARA expression as RT-PCR detected ARA mRNA in the
CEM cells but not in the E16, E25 and E50 sublines (Figure 4). It
therefore is unlikely thatARA is involved in low-level MDR in the
E-series. The second phase represents the increasing resistance
observed in the EI00, E200 and E1000 sublines. This is associated
with increased MRP expression in these sublines and increased
ARA expression in the E200 and E1000 sublines. Although there is
a progressive increase in resistance to several drugs in the El00,
E200 and E1000 sublines, only increasing colchicine resistance
reflects ARA expression in the E200 and EIOO sublines. This
raises the possibility that ARA may play some part in colchicine
resistance in these sublines either through self-association or in
association with MRP.
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